Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia

被引:38
|
作者
Qiao, Q
Lindström, J
Valle, TT
Tuomilehto, J
机构
[1] Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, KTTL, FIN-00300 Helsinki, Finland
[2] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland
关键词
area under ROC curve; hazard ratio; impaired fasting glycemia; impaired glucose tolerance; incidence of diabetes; risk predictor; ROC curve;
D O I
10.1111/j.1464-5491.2003.01054.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the risk of diabetes in subjects with impaired fasting glycemia (IFG) as compared with impaired glucose tolerance (IGT) and normal glucose tolerance. Methods Men (1223) and women (1370) aged 45-64 years and free of diabetes at baseline were followed-up for 10 years, with 26 737 person years accumulated. The incident diabetic cases were identified through the national Drug Register and the Hospital Discharge Register. Results During the 10 years of follow-up, 53 (4.3%) men and 47 (3.4%) women developed diabetes. IFG alone defined 22 (15.5/1000 person years) diabetic cases, which was higher than for subjects with normal fasting glucose. Subjects with isolated IGT identified an additional 34 cases (155% more) which could not be defined by IFG alone. The area under the ROC curve was larger for 2-h glucose (0.77, 95% CI 0.72-0.82) than for fasting glucose (0.65, 0.58-0.71). The multivariate adjusted Cox hazard ratio was higher for isolated IGT (3.9, 95% CI 2.4-6.2) than for isolated IFG (2.3, 0.9-5.7) as compared with subjects with neither IFG nor IGT. Conclusion Both IFG and IGT are risk predictors for diabetes, but IGT defines a much larger target population for prevention.
引用
收藏
页码:1027 / 1033
页数:7
相关论文
共 50 条
  • [1] Progression from normal glucose tolerance to impaired fasting glycaemia and impaired glucose tolerance:: differential roles of insulin resistance and beta cell dysfunction
    Faerch, K.
    Vaag, A.
    Holst, J. J.
    Pedersen, O.
    Glumer, C.
    Borch-Johnsen, K.
    DIABETOLOGIA, 2008, 51 : S85 - S86
  • [2] Metabolic inflexibility is a common feature of impaired fasting glycaemia and impaired glucose tolerance
    Faerch, Kristine
    Vaag, Allan
    ACTA DIABETOLOGICA, 2011, 48 (04) : 349 - 353
  • [3] Fasting glucose and progression of impaired glucose tolerance
    Cockram, CS
    DIABETES CARE, 1999, 22 (02) : 369 - 370
  • [4] Metabolic inflexibility is a common feature of impaired fasting glycaemia and impaired glucose tolerance
    Kristine Færch
    Allan Vaag
    Acta Diabetologica, 2011, 48 : 349 - 353
  • [5] Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention
    Unwin, N
    Shaw, J
    Zimmet, P
    Alberti, KGMM
    DIABETIC MEDICINE, 2002, 19 (09) : 708 - 723
  • [6] Short-term reproducibility of impaired fasting glycaemia impaired glucose tolerance and diabetes The ADDITION study, DK
    Rasmussen, S. S.
    Glumer, C.
    Sandbaek, A.
    Lauritzen, T.
    Carstensen, B.
    Borch-Johnsen, K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 80 (01) : 146 - 152
  • [7] Fasting glucose and progression of impaired glucose tolerance - Response
    Chou, P
    Li, CL
    Tsai, ST
    DIABETES CARE, 1999, 22 (02) : 370 - 370
  • [8] Increased Arterial Stiffness in Subjects with Impaired Glucose Tolerance and Newly Diagnosed Diabetes But Not Isolated Impaired Fasting Glucose
    Li, Chung-Hao
    Wu, Jin-Shang
    Yang, Yi-Ching
    Shih, Chi-Chen
    Lu, Feng-Hwa
    Chang, Chih-Jen
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (04): : E658 - E662
  • [9] Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?
    K. Færch
    K. Borch-Johnsen
    J. J. Holst
    A. Vaag
    Diabetologia, 2009, 52 : 1714 - 1723
  • [10] Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?
    Faerch, K.
    Borch-Johnsen, K.
    Holst, J. J.
    Vaag, A.
    DIABETOLOGIA, 2009, 52 (09) : 1714 - 1723